HIV Guidelines

HIV Treatment and Management

HIV Testing and Prevention

HIV Guidelines

References

  1. Kirby HIV in Australia: annual surveillance short report 2018. Sydney: Kirby Institute, UNSW Sydney;
    2018.
  2. NSW Ministry of NSW HIV Strategy 2016–2020 Quarter 1 2019. Data Report. Available at: https://www.health.nsw.gov.au/endinghiv/Publications/q1-2019-nsw-hiv-data-report.pdf (last
    accessed 2 September 2019).
  3. Queensland Pre-exposure Prophylaxis Demonstration Project Expansion (QPrEPd) Monitoring and Evaluation
    Annual Report Number 1 Available at: https://www.comeprepd.info/wp-content/ uploads/2018/04/qprepd-first-report.pdf
    accessed September 10th 2019 (last accessed 11 September 2019).
  4. Hope A, Haire No‐one’s driving this bus – qualitative analysis of PrEP health promotion for Aboriginal
    and Torres Strait Islander gay and bisexual men. Aust N Z J Public Health 2019 Feb;43:18-23.
  5. Kirby HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report
    2018. Sydney: Kirby Institute, UNSW Sydney; 2018. Available at: https://kirby.unsw.edu.au/report/
    hiv-viral-hepatitis-and-sexually-transmissible-infections-australia-annual-surveillance (last accessed 2
    September 2019).
  6. Medland NA, Chow EPF, Read THR, et Incident HIV infection has fallen rapidly in men who have sex with men
    in Melbourne, Australia (2013–2017) but not in the newly arrived Asian-born. BMC Infect Dis 2018;18:410.
  7. Australian Department of Human Services. Enrolling in Medicare. Available at: https://www.humanservices.gov.au/individuals/subjects/how-enrol-and-get-started- medicare/enrolling-medicare#whocan
    (last accessed 2 September 2019).
  8. Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N; HIV/AIDS Prevention Research
    Synthesis Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic
    review. AIDS Behav 2008;12:1-17.
  9. Centers for Disease Control and HIV Surveillance Reports. 2011; volume 23. Published February 2013.
    Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv- surveillance-report-2011-vol-23.pdf
    (last accessed 2 September 2019).
  10. Escudero DJ, Kerr T, Operario D, Socías ME, Sued O, Marshall BD. Inclusion of trans women in pre-
    exposure prophylaxis trials: a AIDS Care 2015;27:637-41.
  11. Mehrotra ML, Westreich D, McMahan VM, et Baseline characteristics explain differences in effectiveness
    of randomization to daily oral TDF/FTC PrEP between transgender women and cisgender men who have sex with men in
    the iPrEx Trial. J Acquir Immune Defic Syndr 2019; 81:e94-8.
  12. Deutsch MB, Glidden DV, Sevelius J, et al; iPrEx investigators. HIV pre-exposure prophylaxis in
    transgender women: a subgroup analysis of the iPrEx Lancet HIV 2015;2:e512–9.
  13. Shieh E, Marzinke M, Fuchs E, et al (presenter Hendrix C). Transgender women on estrogen have
    significantly lower tenofovir/emtricitabine concentrations during directly observed dosing when compared to cis
    men. Abstract OA23.03. HIV Research for Prevention conference (HIVR4P); 21- 25 October 2018; Madrid, Available
    at: http://www.professionalabstracts.com/hivr4p2018/ iPlanner/#/presentation/205
    (last accessed 2 September 2019).
  14. Hiransuthikul A, Janamnuaysook R, Himmad K, et al; iFACT Study Drug-drug interactions between feminizing
    hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. J Int AIDS Soc
    2019;22:e25338
  15. Cottrell ML, Prince HMA, Schauer AP, et Decreased tenofovir diphosphate concentrations in a transgender
    female cohort: Implications for HIV pre-exposure prophylaxis (PrEP). Clin Infect Dis 2019 Apr 9. pii: ciz290
    [Epub ahead of print].
  16. Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB. Transgender women in
    clinical trials of pre-exposure J Acquir Immune Defic Syndr 2016;72 Suppl 3:S226-9.
  17. Reisner SL, Murchison A global research synthesis of HIV and STI biobehavioural risks in female-to- male
    transgender adults, Glob Public Health 2016;11:866-87.
  18. Reisner SL, Jadwin-Cakmak L, White Hughto JM, Martinez M, Salomon L, Harper Characterizing the HIV
    prevention and care continua in a sample of transgender youth in the U.S. AIDS Behav 2017;21:3312–27.
  19. World Health Organization (WHO). WHO Technical brief: preventing HIV during pregnancy and breastfeeding
    in the context of pre-exposure prophylaxis (PrEP). Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA
    0 IGO. Available at: https://apps.who.int/iris/bitstream/handle/10665/255866/WHO-HIV-2017.09eng.
    pdf;jsessionid=2033F808E98CC3BE9143A7D9AB4D6EEA?sequence=1 (last accessed 2 September 2019).
  20. Mugo NR, Heffron R, Donnell D, et al; Partners in Prevention HSV/HIV Transmission Study T Increased risk
    of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS
    2011;25:1887–95.
  21. Horgan L, Blyth CC, Bowen AC, Nolan DA, McLean-Tooke Pre-exposure prophylaxis for HIV prevention during
    pregnancy and lactation: forget not the women and children. Med J Aust 2019;210:281-4.
  22. Siberry GK, Jacobson DL, Kalkwarf HJ, et Lower newborn bone mineral content associated with maternal use
    of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis 2015;61:996-1003.
  23. Van Dyke RB, Chadwick EG, Hazra R, Williams PL, Seage GR 3rd. The PHACS SMARTT study: assessment of the
    safety of in utero exposure to antiretroviral Front Immunol 2016;7:199.
  24. Mugo NR, Hong T, Celum C, et al; Partners PrEP Study Pregnancy incidence and outcomes among women
    receiving preexposure prophylaxis for HIV prevention: a randomised clinical trial. JAMA 2014;312:362–71.
  25. Heffron R, Mugo N, Hong T, et al; Partners Demonstration Project and the Partners PrEP Study Pregnancy
    outcomes and infant growth among babies with in utero exposure to tenofovir-based preexposure prophylaxis for
    HIV prevention. AIDS 2018;32:1707-13.
  26. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating
    and preventing HIV Recommendations for a public health approach. Second edition 2016. Available at:
    https://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.
    pdf;jsessionid=D9DE8E4B08AE7817BDF0A3439A6F90B6?sequence=1 (last accessed 2 September 2019).
  27. Davies N, Heffron Global and national guidance for the use of pre-exposure prophylaxis during peri-
    conception, pregnancy and breastfeeding. Sex Health 2018;15:501–12.
  28. Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure prophylaxis use by breastfeeding HIV- uninfected
    women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med
    2016;13:e1002132.
  29. The Royal Women’s Hospital Victoria Austr Pregnancy and Breastfeeding Medicines Guide [internet].
    Tenofovir. Available at: https://thewomenspbmg.org.au/medicines/tenofovir (last accessed 2 September 2019).
  30. Benaboud S, Pruvost A, Coffie PA, et Concentrations of tenofovir and emtricitabine in breast milk of
    HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents
    Chemother 2011;55:1315- 7.
  31. Fox J, Brady M, Alexander H, et Tenofovir disoproxil fumarate fails to prevent HIV acquisition or the
    establishment of a viral reservoir: two case reports. Infect Dis Ther 2016;5:65- 71.
  32. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). B Positiv Hepatitis B
    for primary care. Clinical assessment of patients with hepatitis B virus infection [internet]. 2018 update.
    Available at: http://www.hepatitisb.org.au/clinical-assessment-of-patients-with-hepatitis-b-virus-
    infection/ (last accessed 2 September 2019).
  33. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et Virological breakthrough and resistance in patients
    with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011;53:1854-63.
  34. Gilead Full prescribing information. Issued June 2013. Available at: www.accessdata.fda.gov/
    drugsatfda_docs/label/2013/021752s035lbl.pdf (last accessed 2 September 2019).
  35. Purswani M, Patel K, Kopp JB, et Tenofovir treatment duration predicts proteinuria in a multiethnic
    United States Cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J
    2013;32:495-500.
  36. Hosek SG, Rudy B, Landovitz R, et al; Adolescent Trials Network (ATN) for HIVAIDS An HIV preexposure
    prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr 2017;74:21-9.
  37. Hosek SG, Landovitz RJ, Kapogiannis B, et Safety and feasibility of antiretroviral preexposure
    prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr
    2017;171:1063-71.
  38. Havens PL, Stephensen CB, Van Loan MD, et al; Adolescent Medicine Trials Network for HIV/AIDS
    Interventions 117 study Decline in bone mass with tenofovir disoproxil fumarate/emtricitabine is associated with
    hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men
    for HIV preexposure prophylaxis. Clin Infect Dis 2017;64:317-25.
HIV Guidelines

HIV Treatment and Management

HIV Testing and Prevention

Frequently used tools